BIIB241206C145000
- 0.00
- 0.000.00%
Biogen Newsroom
Palantir, MicroStrategy Lead List of Stocks That Could Join Nasdaq 100
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
10 Health Care Stocks With Whale Alerts In Today's Session
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December Starts With a Mixed Market | Live Stock
Express News | Japan Health Ministry Panel Endorses Biogen's ALS Drug Tofersen, Kyodo Says
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Eisai, Biogen Launch Leqembi in South Korea
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
"LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Biogen Put Volume Heavy and Directionally Bearish
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials Driving The Negative Sentiment?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)